Case Study 25 Pcos Treatment

1. Azziz R, Marin C, Hoq L, Badamgarav E, Song P. Health care-related economic burden of the polycystic ovary syndrome during the reproductive life span. J Clin Endocrinol Metab. 2005;90:4650–8.[PubMed]

2. Rotterdam ESHRE/ASRM-Sponsored PCOS Consensus Workshop Group. Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome. Fertil Steril. 2004;81:19–25.[PubMed]

3. Azziz R, Carmina E, Dewailly D, Diamanti-Kandarakis E, Escobar-Morreale HF, Futterweit W, et al. Androgen Excess Society. Position statement: Criteria for defining pcos as a predominantly hyperandrogenic syndrome: An Androgen Excess Society guideline. J Clin Endocrinol Metab. 2006;91:4237–45.[PubMed]

4. Knochenhauer ES, Key TJ, Kahsar-Miller M, Waggoner W, Boots LR, Azziz R. Prevalence of the polycystic ovary syndrome in unselected black and white women of the southeastern United States: A prospective study. J Clin Endocrinol Metab. 1998;83:3078–82.[PubMed]

5. Diamanti-Kandarakis E, Kouli CR, Bergiele AT, Filandra FA, Tsianateli TC, Spina GG, et al. A survey of the polycystic ovary syndrome in the Greek island of Lesbos: Hormonal and metabolic profile. J Clin Endocrinol Metab. 1999;84:4006–11.[PubMed]

6. Michelmore KF, Balen AH, Dunger DB, Vessey MP. Polycystic ovaries and associated clinical and biochemical features in young women. Clin Endocrinol (Oxf) 1999;51:779–86.[PubMed]

7. Asuncion M, Calvo RM, San Millan JL, Sancho J, Avila S, Escobar-Morreale HF. A prospective study of the prevalence of the polycystic ovary syndrome in unselected Caucasian women from Spain. J Clin Endocrinol Metab. 2000;85:2434–8.[PubMed]

8. Azziz R, Woods KS, Reyna R, Key TJ, Knochenhauer ES, Yildiz BO. The prevalence and features of the polycystic ovary syndrome in an unselected population. J Clin Endocrinol Metab. 2004;89:2745–9.[PubMed]

9. Chen X, Yang D, Mo Y, Li L, Chen Y, Huang Y. Prevalence of polycystic ovary syndrome in unselected women from southern China. Eur J Obstet Gynecol Reprod Biol. 2008;139:59–64.[PubMed]

10. Li R, Zhang Q, Yang D, Li S, Lu S, Wu X, et al. Prevalence of polycystic ovary syndrome in women in China: A large community based study. Hum Reprod. 2013;28:2562–9.[PubMed]

11. Kumarapeli V, Seneviratne R de A, Wijeyaratne CN, Yapa RM, Dodampahala SH. A simple screening approach for assessing community prevalence and phenotypes of polycystic ovary syndrome in semiurban population in Srilanka. Am J Epidemiol. 2008;168:321–7.[PubMed]

12. Escobar-Morreale HF, San Millan JL. Abdominal adiposity and the polycystic ovary syndrome. Trends Endocrinol Metab. 2007;18:266–72.[PubMed]

13. March WA, Moore VM, Willson KJ, Phillips DI, Norman RJ, Davies MJ. The prevalence of polycystic ovary syndrome in a community sample assessed under contrasting diagnostic criteria. Hum Reprod. 2010;25:544–51.[PubMed]

14. Nidhi R, Padmalatha V, Nagarathna R, Amritanshu R. Prevalence of polycystic ovarian syndrome in Indian adolescents. J Pediatr Adolesc Gynecol. 2011;24:223–7.[PubMed]

15. Nair MK, Pappachan P, Balakrishnan S, Leena ML, George B, Russell PS. Menstrual irregularity and poly cystic ovarian syndrome among adolescent girls: A two year follow-up study. Indian J Pediatr. 2012;79(Suppl 1):S69–73.[PubMed]

16. Gainie MA, Kalra S. Polycystic ovary syndrome A metabolic malady, the mother of all lifestyle disorders in women Can Indian health budget tackle it in future? Indian J Endocrinol Metab. 2011;15:239–41.[PMC free article][PubMed]

17. Vaidya RA. Polycystic Ovarian Syndrome, a Public Health Issue: Indian perspective oration delivered at the national institute for research in reproductive health ICMR- on the occasion of NIRRH 24 th Foundation Day

18. Mumbai: IIPS; [Last accessed on 2014 Jan 1]. International Institute for Population Sciences (IIPS) and Macro International. 2007. National Family Health Survey (NFHS-3), 2005-06: India: Volume I. Available from: http://www.nfhsindia.org/NFHS-3%20Data/NFHS-3%20NKF/Report.pdf .

19. Misra A, Chowbey P, Makkar BM, Vikram NK, Wasir JS, Chadha D. Consensus statement for diagnosis of obesity, abdominal obesity and the metabolic syndrome for Asian Indians and recommendations for physical activity, medical and surgical management. J Assoc Physicians India. 2009;57:163–70.[PubMed]

20. Khadilkar VV, Khadilkar AV, Borade AB, Chiplonkar SA. Body mass index cut-offs for screening for childhood overweight and obesity in Indian children. Indian Pediatr. 2012;49:29–34.[PubMed]

21. Ferriman D, Gallwey JD. Clinical assessment of body hair growth in women. J Clin Endocrinol Metab. 1961;21:1440–7.[PubMed]

22. Balen AH, Laven JS, Tan SL, Dewailly D. Ultrasound assessment of the polycystic ovary: International consensus definitions. Hum Reprod Update. 2003;9:505–14.[PubMed]

23. Alberti KG, Eckel RH, Grundy SM, Zimmet PZ, Cleeman JI, Donator KA, et al. American Heart Association, World Heart Federation, International Atherosclerosis Society, International Association for the Study of Obesity. Harmonizing the Metabolic Syndrome: A joint interim statement of the International Diabetes Federation Task Force on Epidemiology and Prevention; National Heart, Lung, and Blood Institute; American Heart Association; World Heart Federation; International Atherosclerosis Society; And International Association for the Study Of Obesity. Circulation. 2009;120:1640–5.[PubMed]

24. Norman RJ, Dewailly D, Legro RS, Hickey TE. Polycystic ovary syndrome. Lancet. 2007;370:685–97.[PubMed]

25. Gainie MA, Khurana ML, Eunice M, Gupta N, Diwivedi SN, Gulati MS, et al. Prevalence of glucose intolerance among adolescent and young women with polycystic ovary syndrome in India. Indian J Endocrinol Metab. 2004

26. Goran M, Gower BA. Longitudinal study on pubertal insulin resistance. Diabetes. 2001;50:2444–50.[PubMed]

27. Franks S, White DM. Prevalence of and etiological factors in polycystic ovarian syndrome. Ann N Y Acad Sci. 1993;687:112–4.[PubMed]

28. Taponen S, Martikainen H, Jarvilin MR, Laiatinen J, Pouta A, Hartikainen AL, et al. Hormonal profile of women with self-reported symptoms of oligomenorhea and/or hirsutism: Northern Finland birth cohort 1966 study. J Clin Endocrinol Metab. 2003;88:141–7.[PubMed]

29. Carmina E, Oberfield SE, Lobo RA. The diagnosis of polycystic ovary syndrome in adolescents. Am J Obstet Gynecol. 2010:201–4.[PubMed]

30. Rosenfield RL. Clinical practice. Hirsutism. N Engl J Med. 2005;353:2578–88.[PubMed]

31. Gungor O, Erden G, Bal C, Uguz N, Sezer S, Ozdemir S, et al. The comparison of free androgen index and serum free testosterone levels in women with hirsutism or polycystic ovary syndrome. J Clin Exp Invest. 2011;2:152–6.

32. Li X, Lin JF. Clinical features, hormonal profile, and metabolic abnormalities of obese women with obese polycystic ovary syndrome. Zhonghua Yi Xue Za Zhi. 2005;85:3266–71.[PubMed]

33. Vaidya RA, Joshi B. Adolescent Obesity and PCOS: A dual emergence during childhood and/or pubertal transition. Manuscript accepted for book on Obesity in children and adolescents, An IJCP. In press.

34. Carmina E, Rosato F, Janni A, Rizzo M, Longo RA. Extensive clinical experience: Relative prevalence of different androgen excess disorders in 950 women referred because of clinical hyperandrogenism. J Clin Endocrinol Metab. 2006;91:2–6.[PubMed]

35. Belosi C, Selvaggi L, Apa R, Guido M, Romualdi D, Fulghesu AM, et al. Is the PCOS diagnosis solved by ESHRE/ASRM 2003 consensus or could it include ultrasound examination of the ovarian stroma? Hum Reprod. 2006;21:3108–15.[PubMed]

36. Chang RJ, Nakamura RM, Judd HL, Kaplan SA. Insulin resistance in nonobese patients with polycystic ovarian disease. J Clin Endocrinol Metab. 1983;57:356–9.[PubMed]

37. Dunaif A, Segal KR, Futterweit W, Dobrjansky A. Profound peripheral insulin resistance, independent of obesity, in the polycystic ovary syndrome. Diabetes. 1989;38:1165–74.[PubMed]

38. Shringi M, Vaidya RA, Vaidya AB. Insulin resistance in polycystic ovarian syndrome: A study of 90 patients. J Endocrinol Metab. 2003;1:19–23.

39. Meherji P. From National Institute of Research in Reproductive Health-ICMR. Personal communication

40. Katra A, Nair S, Rai L. Association of obesity and insulin resistance with dyslipidemia in India women with polycystic ovarian syndrome. Indian J Med Sci. 2006;60:447–53.[PubMed]

41. Apridonidze T, Essah PA, Iuorno MJ, Nestler JE. Prevalence and characteristics of the metabolic syndrome in women with polycystic ovary syndrome. J Clin Endocrinol Metab. 2005;90:1929–35.[PubMed]

42. Majumdar A, Singh TA. Comparison of clinical features and health manifestations in lean vs. obese Indian women with polycystic ovarian syndrome. J Hum Reprod Sci. 2009;2:12–7.[PMC free article][PubMed]

1. Speroff L, Fritz MA. Anovulation and the polycystic ovary. In: Speroff L, Fritz MA, editors. Clinical Gynecologic Endocrinology and Infertility. 7th ed. Philadelphia (PA): Lippincott Williams & Wilkins; 2005. pp. 470–483.

2. Azziz R. Diagnostic criteria for polycystic ovary syndrome: a reappraisal. Fertil Steril. 2005;83(5):1343–1346.[PubMed]

3. Lakhani K, Prelevic GM, Seifalian AM, Atiomo WU, Hardiman P. Polycystic ovary syndrome, diabetes and cardiovascular disease: risks and risk factors. J Obstet Gynaecol. 2004;24(6):613–621.[PubMed]

4. Ehrmann DA. Polycystic ovary syndrome. N Engl J Med. 2005;352(12):1223–1236.[PubMed]

5. Dunaif A. Insulin resistance and the polycystic ovary syndrome: mechanism and implications for pathogenesis. Endocr Rev. 1997;18(6):774–800.[PubMed]

6. Rotterdam ESHRE/ASRM-Sponsored PCOS Consensus Workshop Group Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome. Fertil Steril. 2004;81(1):19–25.[PubMed]

7. Azziz R, Carmina E, Dewailly D, et al. Position statement: criteria for defining polycystic ovary syndrome as a predominantly hyperandrogenic syndrome: an Androgen Excess Society guideline. J Clin Endocrinol Metab. 2006;91(11):4237–4245.[PubMed]

8. Adams JM, Taylor AE, Crowley WF, Jr, Hall JE. Polycystic ovarian morphology with regular ovulatory cycles: insights into the pathophysiology of polycystic ovarian syndrome. J Clin Endocrinol Metab. 2004;89(9):4343–4350.[PubMed]

9. Barber TM, Wass JA, McCarthy MI, Franks S. Metabolic characteristics of women with polycystic ovaries and oligo-amenorrhoea but normal androgen levels: implications for the management of polycystic ovary syndrome. Clin Endocrinol (Oxf) 2007;66(4):513–517.[PubMed]

10. Pasquali R, Pelusi C, Genghini S, Cacciari M, Gambineri A. Obesity and reproductive disorders in women. Hum Reprod Update. 2003;9(4):359–372.[PubMed]

11. Boomsma CM, Eijkemans MJ, Hughes EG, Visser GH, Fauser BC, Macklon NS. A meta-analysis of pregnancy outcomes in women with polycystic ovary syndrome. Hum Reprod Update. 2006;12(6):673–683.[PubMed]

12. Gjønnaess H. Ovarian electrocautery in the treatment of women with polycystic ovary syndrome (PCOS). Factors affecting the results. Acta Obstet Gynecol Scand. 1994;73(5):407–412.[PubMed]

13. Patel SM, Nestler JE. Fertility in polycystic ovary syndrome. Endocrinol Metab Clin North Am. 2006;35(1):137–155. vii.[PubMed]

14. Reaven GM. The insulin resistance syndrome: definition and dietary approaches to treatment. Annu Rev Nutr. 2005;25:391–406.[PubMed]

15. Bruner B, Chad K, Chizen D. Effects of exercise and nutritional counseling in women with polycystic ovary syndrome. Appl Physiol Nutr Metab. 2006;31(4):384–391.[PubMed]

16. Moran LJ, Brinkworth G, Noakes M, Norman RJ. Effects of lifestyle modification in polycystic ovarian syndrome. Reprod Biomed Online. 2006;12(5):569–578.[PubMed]

17. Escobar-Morreale HF, Botella-Carretero JI, Alvarez-Blasco F, Sancho J, San Millán JL. The polycystic ovary syndrome associated with morbid obesity may resolve after weight loss induced by bariatric surgery. J Clin Endocrinol Metab. 2005;90(12):6364–6369.[PubMed]

18. Homburg R. Clomiphene citrate – end of an era? A mini-review. Hum Reprod. 2005;20(8):2043–2051.[PubMed]

19. Legro RS, Barnhart HX, Schlaff WD, et al. Clomiphene, metformin, or both for infertility in the polycystic ovary syndrome. N Engl J Med. 2007;356(6):551–566.[PubMed]

20. Messinis IE. Ovulation induction: a mini review. Hum Reprod. 2005;20(10):2688–2697.[PubMed]

21. Sam S, Dunaif A. Polycystic ovary syndrome: syndrome XX? Trends Endocrinol Metab. 2003;14(8):365–370.[PubMed]

22. Grundy SM. Obesity, metabolic syndrome, and coronary atherosclerosis. Circulation. 2002;105(23):2696–2698.[PubMed]

23. Harborne LR, Sattar N, Norman JE, Fleming R. Metformin and weight loss in obese women with polycystic ovary syndrome: comparison of doses. J Clin Endocrinol Metab. 2005;90(8):4593–4598.[PubMed]

24. Glueck CJ, Wang P, Goldenberg N, Sieve-Smith L. Pregnancy outcomes among women with polycystic ovary syndrome treated with metformin. Hum Reprod. 2002;17(11):2858–2864.[PubMed]

25. Palomba S, Orio F, Jr, Zullo F. What is the best first-step therapeutic approach in treating anovulatory infertility in patients with polycystic ovary syndrome? Questions that are still unanswered. Gynecol Endocrinol. 2007;23(5):245–247.[PubMed]

26. Moll E, Bossuyt PM, Korevaar JC, Lambalk CB, van der Veen F. Effect of clomifene citrate plus metformin and clomifene citrate plus placebo on induction of ovulation in women with newly diagnosed polycystic ovary syndrome: randomised double blind clinical trial. BMJ. 2006;332(7556):1485.[PMC free article][PubMed]

27. Creanga AA, Bradley HM, McCormick C, Witkop CT. Use of metformin in polycystic ovary syndrome: a meta-analysis. Obstet Gynecol. 2008;111(4):959–968.[PubMed]

28. Hwu YM, Lin SY, Huang WY, Lin MH, Lee RK. Ultra-short metformin pretreatment for clomiphene citrate-resistant polycystic ovary syndrome. Int J Gynaecol Obstet. 2005;90(1):39–43.[PubMed]

29. Azziz R, Ehrmann D, Legro RS, et al. Troglitazone improves ovulation and hirsutism in the polycystic ovary syndrome: a multicenter, double blind, placebo-controlled trial. J Clin Endocrinol Metab. 2001;86(4):1626–1632.[PubMed]

30. Tang T, Lord JM, Norman RJ, Yasmin E, Balen AH. Insulin-sensitising drugs (metformin, rosiglitazone, pioglitazone, d-chiro-inositol) for women with polycystic ovary syndrome, oligo amenorrhoea and subfertility. Cochrane Database Syst Rev. 2010;(1):CD003053. doi: 10.1002/14651858.CD003053.[PubMed][Cross Ref]

31. Badawy A, Abdel Aal I, Abulatta M. Clomiphene citrate or letrozole for ovulation induction in women with polycystic ovarian syndrome: a prospective randomized trial. Fertil Steril. 2009;92(3):849–852.[PubMed]

32. Carroll N, Palmer JR. A comparison of intrauterine versus intracervical insemination in fertile single women. Fertil Steril. 2001;75(4):656–660.[PubMed]

33. Badawy A, Shokeir T, Allam AF, Abdelhady H. Pregnancy outcome after ovulation induction with aromatase inhibitors or clomiphene citrate in unexplained infertility. Acta Obstet Gynecol Scand. 2009;88(2):187–191.[PubMed]

34. Elnashar A, Abdelmageed E, Fayed M, Sharaf M. Clomiphene citrate and dexamethazone in treatment of clomiphene citrate-resistant polycystic ovary syndrome: a prospective placebo-controlled study. Hum Reprod. 2006;21(7):1805–1808.[PubMed]

35. Nugent D, Vandekerckhove P, Hughes E, Arnot M, Lilford R. Gonadotrophin therapy for ovulation induction in subfertility associated with polycystic ovary syndrome. Cochrane Database Syst Rev. 2000;(4):CD000410. doi: 10.1002/14651858.CD000410.[PubMed][Cross Ref]

36. Parsanezhad ME, Alborzi S, Motazedian S, Omrani G. Use of dexamethasone and clomiphene citrate in the treatment of clomiphene citrate-resistant patients with polycystic ovary syndrome and normal dehydroepiandrosterone sulfate levels: a prospective, double-blind, placebo-controlled trial. Fertil Steril. 2002;78(5):1001–1004.[PubMed]

37. Sastre ME, Prat MO, Checa MA, Carreras RC. Current trends in the treatment of polycystic ovary syndrome with desire for children. Ther Clin Risk Manag. 2009;5(2):353–360.[PMC free article][PubMed]

38. Delbaere A, Smits G, Olatunbosun O, Pierson R, Vassart G, Costagliola S. New insights into the pathophysiology of ovarian hyper-stimulation syndrome. What makes the difference between spontaneous and iatrogenic syndrome? Hum Reprod. 2004;19(3):486–489.[PMC free article][PubMed]

39. Christin-Maitre S, Hugues JN, Recombinant FSH Study Group A comparative randomized multicentric study comparing the step-up versus step-down protocol in polycystic ovary syndrome. Hum Reprod. 2003;18(8):1626–1631.[PubMed]

40. Filicori M, Cognigni GE, Taraborrelli S, et al. Luteinizing hormone activity in menotropins optimizes folliculogenesis and treatment in controlled ovarian stimulation. J Clin Endocrinol Metab. 2001;86(1):337–343.[PubMed]

41. Maggs DG, Buchanan TA, Burant CF, et al. Metabolic effects of troglitazone monotherapy in type 2 diabetes mellitus. A randomized, double-blind, placebo-controlled trial. Ann Intern Med. 1998;128(3):176–185.[PubMed]

42. Palomba S, Zullo F, Diamanti-Kandarakis E, Orio F., Jr . Surgery and laser diathermy. In: Diamanti-Kandarakis E, Nestler JE, Panidis D, Pasquali R, editors. Insulin Resistance and Polycystic Ovarian Syndrome. Totowa (NJ): Humana Press; 2007. pp. 461–477. Chap 33.

43. Al-Fadhli R, Tulandi T. Laparoscopic treatment of polycystic ovaries: is its place diminishing? Curr Opin Obstet Gynecol. 2004;16(4):295–298.[PubMed]

44. Palomba S, Orio F, Jr, Falbo A, et al. Metformin administration and laparoscopic ovarian drilling improve ovarian response to clomiphene citrate (CC) in oligo-anovulatory CC-resistant women with polycystic ovary syndrome. Clin Endocrinol (Oxf) 2005;63(6):631–635.[PubMed]

45. Van Santbrink EJ, Fauser BC. Is there a future for ovulation induction in the current era of assisted reproduction? Hum Reprod. 2003;18(12):2499–2502.[PubMed]

46. Dor J, Shulman A, Levran D, Ben-Rafael Z, Rudak E, Mashiach S. The treatment of patients with polycystic ovarian syndrome by in-vitro fertilization and embryo transfer: a comparison of results with those of patients with tubal infertility. Hum Reprod. 1990;5(7):816–818.[PubMed]

47. Griesinger G, Diedrich K, Tarlatzis BC, Kolibianakis EM. GnRH-antagonists in ovarian stimulation for IVF in patients with poor response to gonadotrophins, polycystic ovary syndrome, and risk of ovarian hyperstimulation: a meta-analysis. Reprod Biomed Online. 2006;13(5):628–638.[PubMed]

48. Hamilton-Fairley D, Kiddy D, Watson H, Sagle M, Franks S. Low-dose gonadotrophin therapy for induction of ovulation in 100 women with polycystic ovary syndrome. Hum Reprod. 1991;6(8):1095–1099.[PubMed]

49. Heijnen EM, Eijkemans MJ, Hughes EG, Laven JS, Macklon NS, Fauser BC. A meta-analysis of outcomes of conventional IVF in women with polycystic ovary syndrome. Hum Reprod Update. 2006;12(1):13–21.[PubMed]

50. Tang T, Glanville J, Orsi N, Barth JH, Balen AH. The use of metformin for women with PCOS undergoing IVF treatment. Hum Reprod. 2006;21(6):1416–1425.[PubMed]

51. Balen A. Polycystic ovary syndrome and cancer. Hum Reprod Update. 2001;7(6):522–525.[

Comments

Leave a Reply

Your email address will not be published. Required fields are marked *